Maintenance rituximab treatment for ANCA-associated vasculitis: to be continued?

Rheumatology (Oxford). 2021 Mar 2;60(3):1010-1012. doi: 10.1093/rheumatology/keaa812.

Authors

Chee Kay Cheung^{1

2}, Stephen P McAdoo^{3

4}

Affiliations

¹ John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK.
² Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
³ Centre for Inflammatory Disease, Imperial College London, UK.
⁴ Renal Medicine, Imperial College Healthcare NHS Trust, London, UK.

PMID: 33351955
DOI: 10.1093/rheumatology/keaa812

No abstract available

Publication types

Comment

MeSH terms

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / drug therapy
Antibodies, Monoclonal, Murine-Derived
Humans
Recurrence
Rituximab / therapeutic use

Substances

Antibodies, Monoclonal, Murine-Derived
Rituximab